Trend turns favourable for GlaxoSmithKline Pharma, key levels to track

GlaxoSmithKline Pharma stock has seen formation of 'Golden Cross' on the daily chart on Thursday; last time the stock saw a similar development, it rallied almost 117% over the next 14 months.

gsk pharma
Rex Cano Mumbai
2 min read Last Updated : Apr 17 2025 | 11:08 AM IST
GlaxoSmithKline Pharma, also known as GSK Pharma, stock has rallied over 22 per cent from its recent low of ₹ 2,401 in the last seven trading sessions. In the process, the stock has swiftly bounced back above its 20-day Daily Moving Average (20-DMA), shows the technical chart.  More importantly, on Thursday April 17, the stock has witnessed the formation of 'Golden Cross' or commonly known as 'Golden Crossover' on the daily charts. The 'Golden Cross' formation means that the 50-DMA of that particular stock or index has crossed over the 200-DMA. This in general implies that the short-term moving average is in ascending angle, thus indicating likely support at higher levels.  Prior to this, GSK Pharma had witnessed formation of 'Death Cross' - which is the opposite of 'Golden Cross' on December 30, 2024, as the 50-DMA slipped below the 200-DMA. Post this negative development, the stock witnessed a 19 per cent fall and eventually bottomed out at ₹ 1,921 in early February.  Historical chart shows that the stock last witnessed a 'Golden Cross' formation on June 30, 2023, wherein the stock price quoted around ₹ 1,415 levels. The stock, thereafter, went on to zoom as much as 116.7 per cent to a high of ₹ 3,067 on August 21, 2024.  ALSO READ: These 2 smallcap stocks trade above 200-DMA after 11 months. Time to buy?  Can this present 'Golden Cross' formation trigger a strong bull run for GSK Pharma? Here are the key levels to watch out as the stock turns favourable on charts.  GlaxoSmithKline Pharma (GSK Pharma)  Current Price: ₹ 2,873  Upside Potential: 21.8%  Support: ₹ 2,815; ₹ 2,566; ₹ 2,545  Resistance: ₹ 2,930; ₹ 3,045; ₹ 3,180  Even as the stock has seen a 'Golden Crossover', GSK Pharma at present is seen testing resistance around its super trend line on the daily chart at ₹ 2,930. Break and sustained trade above the same shall open the doors for a likely rally towards ₹ 3,180, with some interim resistance around ₹ 3,045 levels. The long-term chart suggests the stock can potentially target ₹ 3,500 levels in the coming months.  For now, the bias for the stock is expected to remain favourable as long as it holds above the 200-DMA which stands at ₹ 2,545 levels. Near support for the stock exists at the 20-DMA at ₹ 2,815; while the 50-DMA is at ₹ 2,566. CLICK HERE FOR THE CHART 
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :GlaxoSmithKline PharmaceuticalsGlaxoSmithKlineGSK PharmaTrading strategiesstocks technical analysisMarket technicalsMarket trendsstock market tradingstock market betsStock Recommendationstechnical chartstechnical callsStocks to buyPharma stocks

First Published: Apr 17 2025 | 11:08 AM IST

Next Story